Emcure Pharmaceuticals

From Wikipedia, the free encyclopedia
Emcure Pharmaceuticals Limited
TypeMNC (JVs and subsidiaries)
IndustryPharmaceutical
Founded1983; 38 years ago (1983)
FounderSatish Mehta (CEO)
HeadquartersHinjwadi, Pune, India
Area served
Worldwide
Key people
Namita Thapar
(Executive Director)
Vik Thapar
(President - Corporate Dev & Strategy)
Samit Mehta
(President - R&D)
ProductsTablets
capsules
softgels
injectables
Lyophilized sterile parenterals
Onco products
RevenueIncrease ₹ 6091.80 Crore
(US$ 870.25 million) (FY2021)
Increase ₹ 418.59 Crore
(US$ 59.78 million) (FY2021)
Number of employees
11000+ (2021)
Websitewww.emcure.com

Emcure Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules (both Softgel capsules and hard-gel capsules) and injectables.[1][2]

Indian plants[]

This is the list of Manufacturing facilities based in India[3] -

  • Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets.
  • Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability
  • Oncology injectable facility at Hinjawadi
  • Solid Orals facilities at Jammu and Bhosari
  • API facility at Kurkumbh- US FDA approved
  • Biotech facility at Hinjawadi
  • R&D center at Gandhinagar and plant at Sanand, Ahmedabad.- Sanand facility is US FDA approved

US plant[]

USA - The company has a manufacturing facility and R&D center in East Brunswick, New Jersey, USA.[3]

Capital markets[]

Emcure is planning to raise money through an initial public offering for some time now[4] In 2014, Blackstone sold its stake in Emcure to Bain Capital[5]

Recalls[]

In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus anthracis, Penicillium chrysogenum & E. coli in some samples.[6] Teva recalled several batches of two products due to white tablets showing presence of Yersinia pestis in 2011.[7]

AIDS Initiative[]

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir[8] and Gilead Sciences for Tenofovir as part of their Global Access Programs.

Anticancer portfolio[]

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India.[6] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[9]

Price fixing[]

Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution agreement[10] with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage will pay a $225,000 fine.

In addition, the Company separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay $7.1 million. Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in claims submitted to or purchases by federal healthcare programs

References[]

  1. ^ "Emcure Pharmaceuticals | Leading Global Pharmaceutical Company". Emcure. Retrieved 2021-08-23.
  2. ^ "Emcure Pharmaceuticals: Latest News & Videos, Photos about Emcure Pharmaceuticals | The Economic Times - Page 1". The Economic Times. Retrieved 2021-08-23.
  3. ^ Jump up to: a b "Manufacturing | Emcure Pharmaceuticals". Emcure. Retrieved 2021-08-23.
  4. ^ "Latest News: India News | Latest Business News | BSE | IPO News". Moneycontrol.
  5. ^ "Blackstone to sell Emcure Pharmaceuticals stake to Bain Capital - Indian Express". archive.indianexpress.com.
  6. ^ Jump up to: a b "Business News Today: Read Latest Business news, India Business News Live, Share Market & Economy News". The Economic Times.
  7. ^ "Archived copy". Archived from the original on 2011-05-20. Retrieved 2012-04-25.CS1 maint: archived copy as title (link)
  8. ^ Bureau, Our Corporate (February 17, 2006). "Bristol-Myers outsources AIDS drug to Emcure" – via Business Standard.
  9. ^ "Archived copy". Archived from the original on 2012-08-01. Retrieved 2012-04-12.CS1 maint: archived copy as title (link)
  10. ^ "Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations". www.justice.gov. May 31, 2019.

External links[]

Retrieved from ""